The Evolving Understanding of Histology As an Endpoint in Ulcerative Colitis

Overview

Journal Intest Res

Date 2024 Mar 13

PMID 38475998

Authors

Shintaro Akiyama

Yusuke Miyatani

David T Rubin

Affiliations

Soon will be listed here.

Abstract

A therapeutic goal for patients with ulcerative colitis (UC) is deep remission including clinical remission and mucosal healing. Mucosal healing was previously defined by endoscopic appearance, but recent studies demonstrate that histological improvements can minimize the risks of experiencing clinical relapse after achieving endoscopic remission, and there is growing interest in the value and feasibility of histological targets of treatment in inflammatory bowel disease, and specifically UC. In this review article, we identify remaining challenges and discuss an evolving role of histology in the management of UC.

References

Yoon H, Jangi S, Dulai P, Boland B, Prokop L, Jairath V . Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology. 2020; 159(4):1262-1275.e7. PMC: 7658293. DOI: 10.1053/j.gastro.2020.06.043. View

Kaneshiro M, Takenaka K, Suzuki K, Fujii T, Hibiya S, Kawamoto A . Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission. Aliment Pharmacol Ther. 2021; 53(8):900-907. DOI: 10.1111/apt.16310. View

Christensen B, Hanauer S, Erlich J, Kassim O, Gibson P, Turner J . Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017; 15(10):1557-1564.e1. PMC: 5618439. DOI: 10.1016/j.cgh.2017.02.016. View

Christensen B, Hanauer S, Gibson P, Turner J, Hart J, Rubin D . Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020; 14(10):1345-1353. PMC: 7533894. DOI: 10.1093/ecco-jcc/jjaa068. View

Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S . Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2021; 6(6):429-437. DOI: 10.1016/S2468-1253(21)00062-5. View

Choi C, Al Bakir I, Ding N, Lee G, Askari A, Warusavitarne J . Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut. 2017; 68(3):414-422. PMC: 6581019. DOI: 10.1136/gutjnl-2017-314190. View

Gupta A, Yu A, Peyrin-Biroulet L, Ananthakrishnan A . Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020; 19(9):1800-1813.e4. DOI: 10.1016/j.cgh.2020.09.046. View

Rubin D, Huo D, Kinnucan J, Sedrak M, McCullom N, Bunnag A . Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013; 11(12):1601-8.e1-4. PMC: 3840031. DOI: 10.1016/j.cgh.2013.06.023. View

Yvellez O, Rai V, Sossenheimer P, Hart J, Turner J, Weber C . Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflamm Bowel Dis. 2020; 27(2):203-206. PMC: 7813748. DOI: 10.1093/ibd/izaa047. View

10.

Li K, Strauss R, Marano C, Greenbaum L, Friedman J, Peyrin-Biroulet L . A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials. J Crohns Colitis. 2019; 13(8):1025-1035. DOI: 10.1093/ecco-jcc/jjz022. View

11.

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126(2):451-9. DOI: 10.1053/j.gastro.2003.11.010. View

12.

Mosli M, Feagan B, Zou G, Sandborn W, DHaens G, Khanna R . Development and validation of a histological index for UC. Gut. 2015; 66(1):50-58. DOI: 10.1136/gutjnl-2015-310393. View

13.

Mosli M, Feagan B, Sandborn W, DHaens G, Behling C, Kaplan K . Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014; 20(3):564-75. DOI: 10.1097/01.MIB.0000437986.00190.71. View

14.

Zhang B, Gulati A, Alipour O, Shao L . Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2020; 14(10):1413-1423. PMC: 7533897. DOI: 10.1093/ecco-jcc/jjaa087. View

15.

Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland B, Dulai P . Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2019; 114(5):733-745. DOI: 10.14309/ajg.0000000000000111. View

16.

Mikolajczyk A, Cohen N, Watson S, Ackerman M, Goeppinger S, Hart J . Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis. Inflamm Bowel Dis. 2022; 29(2):222-227. PMC: 10686247. DOI: 10.1093/ibd/izac070. View

17.

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

18.

Li K, Marano C, Zhang H, Yang F, Sandborn W, Sands B . Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020; 159(6):2052-2064. DOI: 10.1053/j.gastro.2020.08.037. View

19.

Ma C, Sedano R, Almradi A, Vande Casteele N, Parker C, Guizzetti L . An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology. 2021; 160(7):2291-2302. PMC: 8851891. DOI: 10.1053/j.gastro.2021.02.035. View

20.

Sands B, Sandborn W, Feagan B, Lichtenstein G, Zhang H, Strauss R . Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018; 12(10):1158-1169. DOI: 10.1093/ecco-jcc/jjy085. View